CClinicalTrials.gg
RecruitingNCT03687528TCAPUpdated Jan 5, 2026

Platelet Inhibitor Treated Patients With Head Injury Trauma Meeting NICE Criteria : is the CT-scan Mandatory ?

An observational study in Head Injury Trauma and Emergencies, sponsored by Rennes University Hospital. Recruiting at 12 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Rennes University Hospital · Observational

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 3 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
3,200
Ages
18 Years and older
Sex
All
01

Study summary

At the emergencies rooms, patients with head trauma meeting one of the NICE criteria, which include antiplatelet inhibitors treatment, are considered as patients with a risk of cerebral haemorrage and are taken systematically for a CT-scanner.

However, there are more and more antiplatelet inhibitor's patient with minor head injury traumas seen at the emergencies room and the efficiency of this NICE criteria is controversial on litterature.

This study aims to determine that the absence of no other NICE criteria than antiplatelet inhibitors is a sufficient condition to eliminate a cerebral haemorrhage for patients with head injury traumas, and conversely, that antiplatelet inhibitors treatment would not be by itself an indication for a CT-scanner.

Read the detailed description

Head injuries are a frequent reason for emergency services, and according to studies, they represent between 5% and 10% of patients treated in emergencies. Among them, 90% are minor head injury traumas. NICE criteria has been defined to establish patients who need a CT-scanner because of a risk of cerebral haemorrhage.

NICE criteria include several conditions including taking antiplatelet inhibitors. However, the real risk of cerebral haemorrhage for theses cases is controversial in litterature. In parallel, more and more patients undergoing antiplatelet inhibitor's treatment are seen in emergencies after a head injury trauma.

In routine protocol at the emergency rooms, these patients are seen for a clinical exam and next submitted to a CT-scanner. If the clinician can't detect a cerebral haemorrage, the patient will return at home.

This study aims to determine that the absence of no other NICE criteria than antiplatelet inhibitors treatment is a sufficient condition to eliminate a cerebral haemorrhage for patients with head injury traumas, and conversely, that antiplatelet inhibitors treatment would not be by itself an indication for a CT-scanner.

This is a diagnostic, case-only, prospective, multicenter study with a blinded primary outcome measure assessment.

As described in routine protocol, in this study antiplatelet inhibitor's patients with head injury trauma will be seen for a clinical exam and next submitted to a CT-scanner. After a month, patient will be called by the clinical center to ask about morbidity and mortality. Especially, clinicans will report on the emergence of a cerebral haemorrhage during this month.

02

Conditions studied

  • Head Injury Trauma
  • Emergencies

Browse trials for

Keywords

  • emergencies
  • platelet inhibitors
  • minor head injury trauma
  • CT-scan
03

In context

Emergencies

1,694 studies on the registry are indexed under Emergencies; 332 are open to participants now.

This study's planned enrollment of 3,200 is above the median of 350 across 715 observational studies indexed under Emergencies.

Browse Emergencies studies →

Lead sponsor

Rennes University Hospital is the lead sponsor of 440 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Major patients undergoing antiplatelet inhibitors treatment which are reported at the clinical exam as having a head injury trauma.

These patients don't meet another NICE criteria :

  • neurological focal deficit
  • amnesia for more than 30 min
  • glasgow score less than 15 after 2 hours
  • loss of consciousness associated with either a high velocity or an age > 65 years old
  • suspicion of a cranial open fracture
  • fracture on cranial basis
  • more than 1 vomit
  • post-traumatic convulsion

Inclusion criteria

  • At least 18 years old
  • Patient with a head injury trauma, described by the patient or seen at the clinical exam
  • Glasgow score between 13 and 15 at the clinical exam
  • Current treatment with antiplatelet inhibitors
  • Informed non opposition form signed

Exclusion criteria

Exclusion Criteria :

  • Absence of CT-scanner
  • Patients with double anti-platelet aggregation
  • Patients on anticoagulants
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
3,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient with minor head injury trauma

    The emergency protocol for antiplatelet inhibitors treated patient with head injury trauma and meeting others NICE criteria involves a clinical exam followed by a CT-scanner.

    Radiation: CT-scanner

Interventions

  • RadiationCT-scanner

    After a clinical exam, patient have a CT-scanner to check any cerebral haemorrhage.

06

What researchers measure

Primary outcomes

  1. Existence of a cerebral haemorrhage at the CT-scanner.

    Cerebral haemorrhage seen at the CT-scanner.

    Time frame: 1 day

Secondary outcomes

  1. Neurosurgeries' rate after one month

    Neurosurgeries' rate after one month

    Time frame: 1 month

  2. Existence of a cerebral haemorrhage associated to death

    Existence of a cerebral haemorrhage associated to death

    Time frame: 1 month

  3. Existence of a cerebral haemorrhage associated to neurosurgery

    Existence of a cerebral haemorrhage associated to neurosurgery

    Time frame: 1 month

  4. Existence of a cerebral haemorrhage associated to hospitalization with more than 24h of intubation

    Existence of a cerebral haemorrhage associated to hospitalization with more than 24h of intubation

    Time frame: 1 month

  5. Existence of a cerebral haemorrhage associated to more than 2 nights at hospital

    Existence of a cerebral haemorrhage associated to more than 2 nights at hospital

    Time frame: 1 month

  6. Death rate after one month

    Death rate after one month

    Time frame: 1 month

07

Study locations

10 of 12 sites recruiting
  • CHU d'Angers
    Angers, France
    • Pierre-Marie ROY, Pr · Contact
    • Delphine DOUILLET · Principal investigator
    Recruiting
  • CHU Brest
    Brest, France
    • Jerome Ducrocq · Contact
    • Jerôme DUCROCQ · Principal investigator
    Recruiting
  • CH Chartres
    Chartres, France
    • Paul BACHELIER, Md · Contact
    • Paul BACHELIER · Principal investigator
    Recruiting
  • CH Le Mans
    Le Mans, France
    • Benjamin WINTENBERGER, Md · Contact
    • Benjamin WINTENBERGER · Principal investigator
    Recruiting
  • CH Bretagne Sud, Lorient
    Lorient, France
    • Nathalie DANIEL, Md · Contact
    • Thomas LE NORMAND · Principal investigator
    • Camille LARUE · Sub investigator
    Recruiting
  • CHU de Nantes
    Nantes, France
    • Emmanuel MONTASSIER, Md · Contact
    • Emmanuel MONTASSIER · Principal investigator
    Recruiting
  • CHU de Poitiers
    Poitiers, France
    • Jeremy GUENEZAN · Contact
    • Jeremy GUENEZAN · Principal investigator
    Recruiting
  • CH Bretagne Sud - Quimperlé
    Quimperlé, France
    • Camille LARUE, Md · Contact
    • Camille LARUE, Md · Principal investigator
    Recruiting
  • CHU de Rennes
    Rennes, 35033, France
    Recruiting
  • CH de Saint Brieuc
    Saint-Brieuc, France
    Not yet recruiting
  • CH de Saint Malo
    St-Malo, France
    • Sabrina PERNET, Md · Contact
    • Sabrina PERNET · Principal investigator
    Recruiting
  • CH Bretagne Atlantique
    Vannes, France
    • Claire Broche-Valence · Contact
    • Claire BROCHE-VALENCE · Principal investigator
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03687528
Lead sponsor
Rennes University Hospital
Responsible party
Sponsor
First posted
Sep 27, 2018
Start date
Jun 15, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 5, 2026

Study contacts

Paul-Georges REUTER, Pr
Contact
paul-georges.reuter@chu-rennes.fr
+33 2 99 28 43 21
Marie-Laure GERVAIS
Contact
marie-laure.gervais@chu-rennes.fr
0299284312
Paul-Georges REUTER, Pr
study director · Rennes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion